The Toxicologist - Society of Toxicology

More documents

Recommendations

Info

Society of Toxicology 2010 Abstract Key Word Index (Continued) The numerals following each key word refer to the relevant abstract number(s). humans............................................ 2066 humoral immune response.............. 1525 Huntington disease................... 993, 997 hydrofluoric acid.................. 1175, 1192 hydrogen peroxide.......................... 1215 Hydroquinone........................... 514, 780 hypercholesterolemia........................ 227 hyperglycemia................................ 1775 Hyperoxia............................... 457, 2120 hyperoxia lung injury....................... 598 hypersensitivity......... 304, 305, 316, 618 Hypersensitivity dermatitis............. 1304 Hypertension........................... 663, 1498 Hyperthyroidism............................. 1714 hypertrophy..................................... 1733 Hypo-allergenic.............................. 1176 hypothalamic-pituitary axis.............. 406 hypothalamic-pituitary-adrenal axis.................................................. 2087 hypothyroidism............... 158, 160, 1714 Hypoxia...... 153, 513, 1212, 1636, 2175 Hypoxia Inducible Factor..... 1196, 2137 Hypoxia Inducible Factor (HIF)....... 512 Hypoxia-Ischemia........................... 1218 ICH Guidelines................................... 11 ICH S6............................................ 1435 ICH S9 guidance............................. 1787 Idiosyncratic......... 313, 365, 1441, 2125 idiosyncratic drug reactions....... 16, 314, 315, 1071 Idiosyncratic Hepatotoxicity.......... 1071 Idiosyncratic liver toxicity.............. 2123 IdMOC.................................... 322, 1411 idursulfase-IT................................. 1061 IFN beta.......................................... 1046 IFNgamma...................................... 1556 Ig heavy chain....... 71, 1536, 1538, 1539 IgE............................................ 296, 302 IGF-1................................................ 583 III-V semiconductors...................... 2043 IL-1 receptor..................................... 417 IL-8................................... 130, 749, 958 image analysis................................ 1113 immune............................................. 327 immune cells..................................... 328 immune complex...................... 615, 620 Immune dysfunction....................... 2195 immune function..................... 935, 2192 immune response............................ 1722 immune-competent........................... 291 immune-mediated............................... 16 immunity suppression....................... 631 immunogenicity............ 619, 1046, 1990 immunohistochemistry................... 1656 immunomodulation........ 371, 540, 2052, 2053, 2056, 2057 Immunomodulator............................ 747 immunomodulators............................... 4 immunophenotyping... 1979, 1983, 1984 Immunosuppression... 1530, 1980, 1989, 1997, 2054, 2184 immunotoxicity.................. 78, 304, 305, 309, 326, 1177, 1523, 1542, 1562, 1608, 1978, 1982, 1993, 1996, 2124, 2184, 2185, 2189, 2196 Immunotoxicology.. 312, 315, 317, 536, 1189, 1722, 1980, 1981, 1991, 2052, 2053, 2054, 2055, 2180, 2181, 2188 impedance....................................... 1657 Imposex............................................ 436 Impurities.................................. 547, 552 impurity.......................................... 1118 in silico............... 195, 1348, 1386, 1450 in utero.............................................. 971 in utero exposure............................ 1485 in vitro........................ 99, 102, 164, 249, 442, 471, 473, 556, 613, 650, 819, 1116, 1245, 1252, 1401, 1555, 1611, 1658, 1702, 1960, 2102, 2190 in vitro - in vivo................................. 250 in vitro airway model................ 470, 477 in vitro alternative.... 107, 112, 303, 306, 1598 in vitro Alternative Method..... 412, 1926 in vitro alternatives..................... 97, 500 in vitro Animal Alternative Method.103, 1966 in vitro assay..................................... 181 in vitro assays................. 366, 380, 1982 in vitro cytotoxicity................. 114, 1692 in vitro developmental neurotoxicity testing............................................... 181 in vitro dosimetry................................ 92 in vitro HTS........................................ 98 in vitro human skin model.............. 2060 in vitro Human Skin Models............ 112 in vitro micronucleus assay.... 472, 1172 in vitro model................ 753, 1389, 1540 in vitro models................................ 1124 in vitro screening..... 109, 118, 181, 190, 1051 in vitro skin absorption........... 891, 2050 in vitro Skin Diffusion.................... 2047 in vitro skin model.................... 477, 478 in vitro testing....... 491, 792, 1118, 2217 in vitro Tests...................................... 405 in vitro to in vivo extrapolation......... 895 in vitro toxicology............................. 487 in vitro /in vivo.................................. 280 in vivo................... 908, 922, 1731, 1963 in vivo genotoxicity assay............... 1110 in vivo imaging with PET and MRI................................................. 1388 in vivo micronucleus assay.. 1106, 1109, 1129 in vivo mutation.............................. 1355 in vivo Percutaneous Absorption..... 342, 2047 in vivo toxicity................................ 1495 In-Utero............................................ 846 in-vitro in-vivo correlation.............. 2126 In-vitro model for skin irritation....... 499 inbred mouse strains......................... 366 IND................................................. 2208 individual susceptibility.................. 1861 Individual Variation........................ 1071 indole.............................................. 1647 indoor.............................................. 1867 inducible pluripotent cells.................. 47 Industrial solvents............................. 887 Inert................................................. 1901 infant................................................. 379 infants............................................... 319 Infection.......................... 422, 740, 2057 Inflammation............. 93, 130, 275, 281, 290, 350, 537, 578, 730, 732, 733, 735, 738, 959, 986, 992, 1310, 1316, 1400, 1493, 1512, 1516, 1553, 1619, 1626, 1737, 1751, 1783, 1992, 2015 Inflammatory cytokine................... 1557 Inflammatory cytokines.... 74, 736, 1545 inflammatory heart disease............. 1419 Inflammatory liver injury............... 2134 influenza................................. 956, 2179 Influenza A virus............................ 1531 Informatics.............................. 211, 1079 Informative Prior Distributions......... 873 informed substitution...................... 2219 infusion........................................... 1185 ingestion......................................... 1941 ingestive behavior........................... 2087 Inhalation..... 19, 22, 323, 367, 370, 608, 835, 927, 928, 1020, 1032, 1398, 1401, 1478, 1479, 1480, 1492, 1510, 1516, 1518, 1521, 1523, 1794, 2179, 2188 inhalation........................................ 1514 Inhalation exposure.237, 344, 929, 1495 inhalation toxicity....... 1171, 1395, 1403 inhalation toxicology..... 934, 939, 1169, 1499, 1503, 1506, 1509 inhalational toxicology................... 1511 injection.......................................... 1186 injury............................. 579, 1597, 1828 innate defense response.................... 754 innate immune system.................... 1543 Innate Immunity............................... 676 iNOS................... 336, 1075, 1076, 1077 insecticide....................................... 1181 Insecticides..................................... 1241 insulin................................... 1677, 1824 insulin like growth factor acid labile subunit............................................ 1143 Insulin Resistance......... 961, 1053, 1507 integrin linked kinase...................... 1950 Interaction................... 1139, 1572, 1882 interferon........................................ 1672 Interindividual variability factor..... 1914 interleukin-17..................................... 77 interleukin-4................................... 1541 intestinal absorption.......................... 949 intestinal barrier................................ 786 Intestinal inflammation..................... 711 intestinal Paneth cells....................... 754 intracellular calcium................ 217, 223, 373, 976 Intracellular Concentration............. 1595 Intracellular Staining...................... 1985 intramuscular injection................... 1054 Intraspecies Variability..................... 874 intrathecal................... 1061, 1185, 1186 intratracheal instillation.................. 1490 Intravenous............................. 922, 1484 Intravenous infusion......................... 851 intravenous injection....................... 1083 Intrinsic Apoptosis............................ 138 invasion................................. 1761, 2157 investigational toxicology............... 1375 iodide.............................................. 2099 iodine................................................ 822 Iodine deficiency............................ 2094 ion channel...................................... 2030 ion channels.................................... 2029 Ionic liquids.................................... 1584 iPLA 2 .............................................. 1663 iPS cells........................................ 48, 52 IRIS................................................. 1925 Iron..................... 983, 1220, 1365, 1424 iron oxide nanoparticle..................... 256 Ischemia reperfusion...................... 1214 ischemia/reperfusion......................... 810 isocyanates...................................... 2017 isolated rat hepatocytes................... 1955 Isomer............................................... 876 Isoniazid........................................... 448 isotherms......................................... 1161 Isothiocyanates............................... 1781 isozyme........................................... 1309 jacket telemetry................................ 605 Japanese Medaka............................ 1204 JARID1A.......................................... 153 jet fuel........................... 875, 1523, 2188 joint compound............................... 1873 Joint Toxicity of Mixtures................ 248 JP-8................................................... 876 JP-8 jet fuel..................................... 1265 juice................................................ 1135 Junction........................................... 1482 juvenile.606, 927, 928, 1052, 2116, 2119 juvenile studies............................... 1583 Juvenile Toxicity............................. 2114 K-ras................................................. 628 K99/R00........................................... 662 kahweol........................................... 1766 Keap1................................................ 975 keratin adducts................................ 1329 Keratinocyte Differentiation............. 675 keratinocytes..................................... 259 ketamine........................... 163, 179, 845 kidney...................... 579, 807, 812, 814, 820, 823, 824, 1313, 1314, 1330, 1443, 1713, 1813 kidney biomarkers.............................. 12 Kidney Calcinosis........................... 1157 Kidney Cancer................................ 1679 kidney injury molecule-1.................. 806 Kidney Injury Molecule-2................ 821 Kidney toxicity................................. 817 kinase...................................... 187, 1361 kinases.................................... 632, 1818 KLH...................................... 1988, 1994 Knockout........................................ 1962 Knockout Mice......................... 524, 933 knockout rats.................................... 904 knowledge......................................... 941 Knowledgebase................................. 213 knowledgebases.................................... 1 Kupffer Cell............................ 524, 1965 Kupffer cells........................... 744, 1303 L. monocytogenes........................... 1162 L1 retrotransposon............................ 150 laboratory animals........................ 3, 588 Lactating rat and pup........................ 894 lambda-cyhalothrin......................... 1892 lamellarin........................................ 1779 LAMP-2.......................................... 1656 Langerhans cells............................... 307 large animals..................................... 925 laser capture microdissection....582, 1655 late phase............................................ 63 Lavendamycin antitumor agents....... 724 LC-APCI-MS................................. 1326 LC-MS/MS............................... 719, 761 LC/MS............................................ 1307 LC/MS/MS..................................... 1402 lead.......................... 245, 439, 666, 984, 989, 1254, 1602, 1603, 1610, 1614, 1840, 1841, 1843, 1844, 1972 lead (Pb)................................ 1431, 1600 lead exposure.................................... 147 lead neurotoxicity....... 1604, 1609, 2026 Lead poisoning............................... 1842 learning................................... 465, 1614 learning and memory................ 403, 989 lectins................................................ 259 left ventricular hypertrophy............ 2162 legal.................................................. 942 Leiomyoma....................................... 413 lens explant cultures......................... 469 leptin................................................. 400 leptomycin B.................................... 727 leukemia........... 123, 143, 514, 520, 665 leukemia/lymphoma......................... 128 Leukemogenesis............................... 848 Leydig cell...................................... 2092 Leydig cells.................................... 1019 Libby Amphibole............................ 1874 Life-stage........................................ 1721 life-stage adjustment....................... 1912 life-stage susceptibility..................... 783 lifestage............................................. 656 linezolid.......................................... 1070 Linkage Disequilibrium.................... 947 lipid......................................... 571, 1356 lipid metabolism......... 1357, 1360, 1361 Lipid peroxidation.......................... 1509 Lipid Rafts...................................... 1669 Lipids................................................ 593 Lipin............................................... 1360 lipin 1.............................................. 1737 lipopolysaccharide........ 757, 1965, 2125 lipotoxicity...................................... 1770 liver...................... 84, 89, 219, 228, 309, 557, 969, 1092, 1137, 1138, 1344, 1346, 1347, 1348, 1440, 1441, 1442, 1534, 1581, 1632, 1633, 1636, 1639, 1644, 1715, 1950, 1962, 1965, 2115, 2124, 2127, 2132, 2138, 2139 liver cancer..................................... 1343 Key Word Index SOT 2010 Annual Meeting 501
49 th Annual Meeting and ToxExpo Abstract Key Word Index (Continued) The numerals following each key word refer to the relevant abstract number(s). Key Word Index liver carcinogenesis.................. 533, 534 liver injury................. 83, 148, 269, 621, 626, 750, 1051, 1952, 1956 Liver Regeneration......................... 1537 Liver Toxicity... 1048, 1410, 2013, 2074 liver X receptor............................... 1069 Livestock........................................ 1940 livestock health............................... 1018 LKB1-AMPK................................. 1393 LLNA................................................ 111 LNCaP............................................ 1905 LOAEL............................................. 839 local lymph node assay................... 1806 local lymph node assay (LLNA).... 1804 Locomotion..................................... 1262 long term corneal culture.................. 104 long term toxicity............................. 277 loss of heterozygosity....................... 694 low dose............................................ 678 Low dose effects............................. 1454 low-dose.............................................. 39 low-dose extrapolation......... 1791, 1931 low-dose linearity............................... 38 LPS................................................... 750 LRP1............................................... 1841 luciferase reporter........................... 1540 Lunar dust................................. 292, 375 lung.......................... 286, 329, 350, 735, 800, 1400, 1475, 2072, 2073, 2106, 2151 lung cancer....................... 122, 356, 628, 727, 734, 741 Lung carcinogenesis......................... 676 Lung Development......................... 1970 lung dosimetry.................................. 869 Lung Fibrosis.................................... 793 lung function............................. 336, 926 Lung inflammation.......... 737, 776, 939, 1473, 1497, 1665 lung injury...... 257, 344, 457, 804, 1031 Lung Modeling......................... 871, 872 Lung slice........................................... 93 Lung surfactant................................. 797 lupus nephritis................................ 1784 lymphoblast...................................... 201 Lymphocryptovirus (LCV)............... 935 Lymphocyte.................................... 1060 Lymphocyte subset......................... 1304 Lymphocyte Transformation Test (LTT).............................................. 1049 lymphocytes............................ 536, 2182 lymphoid toxicity............................ 1227 Lymphoma...................... 520, 665, 1782 lyse.................................................. 1987 Lysosome.............................. 1212, 1657 lysosomes......................................... 770 MABEL.......................................... 1003 Macaca fascicularis........................ 1036 macaque............................................ 917 Machine Learning Algorithms.......... 193 macrophage............... 34, 583, 766, 1545 Macrophages.... 32, 599, 676, 745, 1658, 1692, 2182 Magnetic Resonance Imaging.......... 939 Magnetic Resonance Spectroscopy................................... 1000 Maize.............................................. 1456 Malaria............................................ 1241 malathion........................................ 1254 MALDI Imaging Mass Spectrometry..................................... 167 MALDI-TOF.................................. 1667 MALDI-TOF-MS............................. 428 Male and female fertility.................. 376 male infertility.................................. 390 male pubertal assay......................... 2111 male reproduction............................. 407 Male Reproductive Toxicity..... 289, 561 Male reproductive toxicology........... 393 mammal-to-fish................................ 437 mammalian toxicology............. 13, 1904 Mammary Cancer............................. 188 mammary carcinogenesis................. 831 mammary gland................................ 839 mammary stem cells....................... 2002 maneb................................... 1244, 1260 Manganese............... 272, 884, 885, 988, 990, 997, 999, 1000, 1002, 1296, 1600, 1890, 2038, 2173 manganese and lead............................ 23 Manganese neurotoxicity....981, 985, 998 manganese synergism....................... 986 manganese toxicity... 978, 979, 980, 982 Manganese transport......................... 993 Manganeses.................................... 1909 Manganism....................................... 982 Manufactured Gas Plants................ 1039 Manzate................................ 1286, 1291 MAP kinase.............................. 629, 631 MAP kinases............................. 627, 630 MAPK..................................... 628, 1663 mass spectrometry............................ 341 mast cell........................ 795, 1502, 1561 mast cells................................ 726, 1772 maternal diet manipulation and mercury exposure........................... 1977 maternal toxicity............................... 397 mathematical modeling.................... 897 Mating............................................... 392 matrix metalloproteinase................ 1511 Matrix metalloproteinase-9.............. 909 matrix metalloproteinases............... 2060 Matrix Metalloproteinases-9.......... 1761 Maturation...................................... 1568 MCF-7 cells.................................... 2006 Mcl-1.............................................. 1219 MCSF............................................... 484 MDA-kb2.......................................... 113 MDA-MB-231................................ 2007 MDMA........................................... 1088 MDR1............................................. 1768 MDSCs........................................... 1527 meat grade...................................... 1136 mechanism...................................... 1932 mechanism of action....................... 2103 mechanisms.................................... 2039 medaka............................ 686, 687, 1903 media refinement.............................. 104 medical device.................................... 88 Medical devices.................... 1187, 1944 Megakaryocyte............................... 2168 megalin............................................... 86 megaloblastic anemia..................... 1058 MEHP......................... 1482, 1483, 1664 Meiosis............................................. 460 Melamine.... 319, 817, 1140, 1151, 1158 melanocytes...................................... 497 Melatonin.......................................... 867 memantine...................................... 1277 Membrane Cholesterol................... 1669 menthol................................... 447, 1311 mercuric sulfide.............................. 1177 mercury.............. 245, 1295, 1786, 1830, 1831, 1832, 1833, 1835, 1836, 1838 mercury toxicity................................ 987 Mesenchymal Stem Cell................. 1196 Mesothelioma..... 739, 1397, 1546, 1547 Meta-analysis.......................... 670, 1886 Metabolic activation....... 696, 699, 1968 metabolic deactivation...................... 466 Metabolic deranegement................. 1063 Metabolic Disease............................ 633 Metabolic Diseases........................... 209 metabolic imprinting...................... 1977 metabolic interactions....................... 243 Metabolic Pathways.......................... 209 metabolic poise............................... 1080 metabolic syndrome......... 415, 553, 554, 557, 584, 1053, 1356, 1362, 1959, 1975, 2079 Metabolism................ 28, 211, 443, 444, 445, 450, 477, 571, 634, 643, 889, 1095, 1358, 1366, 1566, 1573 Metabolism-mediated toxicity......... 948, 2075 Metabolites........................... 1301, 1378 Metabolizing enzymes.............. 486, 501 metabolomics........... 207, 364, 534, 580, 1059, 1293, 1331, 1611, 1629, 1646, 2043, 2214 Metabonomics................... 57, 636, 720, 809, 1637, 1638, 2128, 2209 metal...... 20, 130, 270, 438, 1811, 1814, 1845, 2149 metal oxides...................................... 373 metallic nickel.................................. 528 metallothionein.... 146, 434, 1367, 1711, 1813, 1814, 1815, 1816 metallothioneins............................. 1465 Metals.................. 19, 90, 286, 794, 838, 860, 879, 944, 998, 1290, 1367, 1427, 1815, 1817, 1819, 1879, 1942, 2037, 2072, 2073, 2118, 2160, 2162, 2165, 2168, 2169, 2176 Metals and Minerals............. 2034, 2035 Metformin............................. 1584, 1710 Methacrylonitrile............................ 1193 Methamidophos.............................. 1900 Methamphetimine........................... 1575 Methanol........................................... 708 methanol metabolism........................ 834 methemoglobinemia....................... 1760 Method development... 475, 1132, 1588, 1589 method validation................. 1587, 1926 methods........................................... 1918 methods and models......................... 170 Methoxychlor........................... 395, 399 methyl formate................................ 1023 Methyl mercury.............................. 1834 Methylation..................... 453, 945, 1345 methylmercury......... 378, 705, 841, 847, 976, 977, 994, 1001, 1025, 1394, 1601, 1613, 1837, 1839 Methylmercury neurotoxicity.......... 976, 977, 1607, 2026 methylphenidate............................. 1251 metofluthrin.................................... 1868 Metylmercury................................... 975 MHC-II........................................... 1559 MIC-1............................................... 746 micotoxins...................................... 1464 micro RNA..................................... 1715 microarray.................... 855, 1649, 1719, 1832, 1845 microarray analysis................. 810, 1625 microarrays..................................... 2212 Microcystin..................................... 1969 Microcystins..................................... 230 microcystis........................................ 757 Microdialysis.................................. 1575 microelectrode array....................... 2032 Microencapsulation.......................... 285 microfluidics..................................... 118 microglia....757, 1272, 1274, 1279, 1839 micronuclei......... 691, 1112, 1115, 1141 micronucleus............... 1108, 1113, 1117 micronucleus assay......................... 1111 micronucleus test............................ 1122 Micronutrients................................ 2035 microorganisms................................ 427 microPET.......................................... 163 Microphysiometer............................. 100 microRNA........................... 53, 56, 119, 172, 1347, 1463 microRNAs....................................... 850 microsomal epoxide hydrolase...... 1103, 1104 Microtox................................... 251, 252 Microtubule Associated Protein...... 1267 microvascular........................ 1728, 1730 Milk................................................ 1891 Minerals............................................ 609 Minimal Risk Level (MRL)............ 1945 mini-pig........................ 903, 1073, 1980 Minipigs............................................ 601 Mink................................................. 430 Minocycline.................................... 1213 miRNA...... 533, 1651, 1756, 2040, 2201 Mitochondria............... 82, 84, 369, 633, 634, 635, 636, 712, 767, 769, 813, 814, 1075, 1080, 1212, 1255, 1319, 1421, 1422, 1423, 1424, 1425, 1426, 1615, 1633, 1673, 1731, 2117, 2121 Mitochondria Dysfunction.................. 79 Mitochondria membrane potential... 980 mitochondria toxicity........................ 980 Mitochondrial............... 81, 94, 95, 1743 mitochondrial biogenesis.................. 637 Mitochondrial DNA damage............ 184 mitochondrial dysfunction....... 186, 637, 978, 1278, 1719 Mitochondrial dysfuntion............... 1676 mitochondrial heam transporter...... 1089 Mitochondrial Oxidative Stress....... 764, 2129, 2133 Mitochondrial Permeability Transition... 2130 mitochondrial protein synthesis...... 1070 mitochondrial toxicity....... 10, 200, 637, 1070 Mitogen activated protein kinase...... 592 Mitogen-activated protein kinases....2093 mitogens........................................... 674 mitotic spindle.................................. 799 Mixed Amphetamine Salts............... 669 mixture.......................... 324, 1570, 2189 mixture toxicity................................ 251 Mixtures................... 242, 245, 246, 247, 250, 561, 562, 568, 569, 972, 1882 MMP............................................... 1811 MMP-9....................... 1710, 1767, 1769 MMPs..................................... 368, 2003 MN/Comet...................................... 1117 MnSOD............................................. 240 MNU................................................. 911 MOA................................................. 521 mode of action.... 139, 1129, 1721, 1908 Mode-of-Action.......................... 5, 2104 Model.............................................. 1877 Modeling........................................... 249 mold.................................................. 298 molds.............................................. 1302 Molecular.......................................... 858 Molecular Biology............................ 633 Molecular Docking............... 1380, 1468 molecular docking model............... 2112 molecular imprinted polymer stir bar.337 Molecular Mechanisms.................. 1356 molecular mimicry............................ 667 molecular modeling................ 203, 1097 molecular targets for toxicity............ 203 monkey............ 1055, 1056, 1662, 1722, 1987, 1988 monkey fetal serum........................ 1990 monkey primary gall bladder epithelial cells................................................... 117 Monkey Study................................. 2187 Monkeys......................................... 1586 monoclonal antibody....... 617, 618, 619, 842, 1043, 1044, 1437, 1438 monocyte adhesion........................... 957 Monomethylarsonous acid........ 953, 954 Moon Dust, Lunar Dust.................. 1859 mortality................................. 996, 1035 motorcycle exhaust......................... 1520 mouse..................... 363, 826, 830, 1846, 2086, 2190 Mouse embryonic stem cells.......... 1691 mouse Leydig cells......................... 2089 502 SOT 2010 Annual Meeting
Page 1 and 2:
The Toxicologist Supplement to Toxi
Page 3 and 4:
The Toxicologist Supplement to Toxi
Page 5 and 6:
1 BIOLOGICAL PATHWAY ANALYSIS: AN I
Page 7 and 8:
11 ICH INITIATIVES FOR CONDUCTING P
Page 9 and 10:
models. Experimental approaches and
Page 11 and 12:
30 SILICA AND ASBESTOS IMMUNOTOXICI
Page 13 and 14:
40 NONCANCER TOXICITY POTENTIAL AT
Page 15 and 16:
ased products for patient administr
Page 17 and 18:
nase regulates Hsp27-induced reorga
Page 19 and 20:
exposure resulted in splenomegaly.
Page 21 and 22:
We investigated the effect of imati
Page 23 and 24:
well plate prevented free cell move
Page 25 and 26:
98 DERIVING SIGNATURES OF IN VIVO T
Page 27 and 28:
sulfate, cinnamic aldehyde, 2,4-din
Page 29 and 30:
The final product will be a system
Page 31 and 32:
mercially available STP brands by m
Page 33 and 34:
for six weeks, with 10 mg/kg azoxym
Page 35 and 36:
eceived RES post-TCDD exposure when
Page 37 and 38:
morigenesis. Knocking down of JARID
Page 39 and 40:
163 MICROPET IMAGING OF [18F]-DFNSH
Page 41 and 42:
These results are comparable to tha
Page 43 and 44:
activity as assessed by lever press
Page 45 and 46:
for measured physico-chemical param
Page 47 and 48:
199 DEVELOPMENT OF A MULTIPARAMETER
Page 49 and 50:
To cause PLD, a drug needs to enter
Page 51 and 52:
In contrast to the parent PBDEs and
Page 53 and 54:
transiently transfected HEK 293 cel
Page 55 and 56:
TCDD exposure, 24 h prior to a 20 %
Page 57 and 58:
244 NON-ADDITIVE EFFECTS OF PCB153
Page 59 and 60:
253 COMPARISON OF MIXTURE TOXICITY
Page 61 and 62:
two cerium oxide nanoparticles of v
Page 63 and 64:
271 SIZE-DEPENDENT EFFECTS OF TUNGS
Page 65 and 66:
adigms such as Tox 21 and Toxcast,
Page 67 and 68:
QDs with emission maximum at 800nm
Page 69 and 70:
Cleveland, while others were found
Page 71 and 72:
without the need of animal testing.
Page 73 and 74:
Conclusions: These results are cons
Page 75 and 76:
ing oxime reactivation and organoph
Page 77 and 78:
335 A NON-OXIME IMPROVES SURVIVAL I
Page 79 and 80:
alties suffer from permanent lung i
Page 81 and 82:
ies have established inflammatory b
Page 83 and 84:
363 GENETIC VARIATION IN ISOGENIC M
Page 85 and 86:
372 EVALUATING THE BIOLOGICAL INTER
Page 87 and 88:
dose of 1/20 LD50 (400 mg/kg.bwt) f
Page 89 and 90:
median CR-adjusted isoflavone conce
Page 91 and 92:
data indicate that AhR deletion pro
Page 93 and 94:
February 2006). The rabbit is one o
Page 95 and 96:
tal neurotoxicity (DNT) test (OECD
Page 97 and 98:
of selected microorganisms that are
Page 99 and 100:
BVI. Histopathological analysis was
Page 101 and 102:
446 MOLECULAR CLONING AND CHARACTER
Page 103 and 104:
portant in predicting risk. CYPs 1A
Page 105 and 106:
ats, which involves metabolic activ
Page 107 and 108:
473 BOVINE CORNEAL OPACITY AND PERM
Page 109 and 110:
482 TYPE III DEIODINASE (D3) IS PRO
Page 111 and 112:
tancy evaluation and ranking of bat
Page 113 and 114:
501 CHARACTERIZATION OF ESTERASE, G
Page 115 and 116:
510 REDOX CYCLING BY ENDOGENOUS 2-
Page 117 and 118:
prostate cancer cells. All 8 BEL de
Page 119 and 120:
metallic nickel nanoparticles. Acti
Page 121 and 122:
variety of more or less reactive ch
Page 123 and 124:
550 QUALIFICATION STRATEGIES-GENOTO
Page 125 and 126:
ferentiation, and 3) how mixtures o
Page 127 and 128:
572 LOW-CHRONIC ARSENIC EXPOSURE: E
Page 129 and 130:
582 IDENTIFICATION OF SENSITIVE URI
Page 131 and 132:
duced by the genetic outcross of fe
Page 133 and 134:
fects of new compounds are equally
Page 135 and 136:
acterize the current state of the s
Page 137 and 138:
620 CHARACTERIZATION OF POTENTIAL I
Page 139 and 140:
ways. Moreover, both MAP kinase and
Page 141 and 142:
641 POPS IN THE U.S. POPULATION AND
Page 143 and 144:
studies such as the NCS, consider h
Page 145 and 146:
the beginning of the academic caree
Page 147 and 148:
trophil infiltration, a significant
Page 149 and 150:
tactic response and optokinetic res
Page 151 and 152:
usually high spontaneous PIG-A MFs.
Page 153 and 154:
699 PROMUTAGEN ACTIVATION AND P450
Page 155 and 156:
oxodG in bone marrow, spleen, kidne
Page 157 and 158:
718 GENOTOXICITY OF ORGANIC EXTRACT
Page 159 and 160:
ment were 18.0 and 4.5 nM for BEAS-
Page 161 and 162:
strongest activation of nuclear fac
Page 163 and 164:
746 MACROPHAGE INHIBITORY CYTOKINE-
Page 165 and 166:
screening of cell migration. High-c
Page 167 and 168:
dase inhibition). In contrast, inhi
Page 169 and 170:
mice; the decrease was more pronoun
Page 171 and 172:
Markers of oxidative damage reached
Page 173 and 174:
793 PULMONARY RESPONSE, OXIDATIVE S
Page 175 and 176:
cilitate clinical and industrial ap
Page 177 and 178:
sion of p-p38, p-p53, p21 and cycli
Page 179 and 180:
821 KIDNEY INJURY MOLECULE-2 GENE D
Page 181 and 182:
commercial applications, and have b
Page 183 and 184:
developmental effects. The residual
Page 185 and 186:
strand breaks in an in vitro model
Page 187 and 188:
etate (immunotoxicity). 2,4-D was t
Page 189 and 190:
867 MELATONIN AMELIORATES CYCLOPHOS
Page 191 and 192:
pharmacokinetic (PBPK) models. Ten
Page 193 and 194:
of radiolabeled Mn (carrier-free 54
Page 195 and 196:
893 UNVEILING ASSOCIATIONS BETWEEN
Page 197 and 198:
using area under the concentration
Page 199 and 200:
912 COMMERCIAL FISH DIETS INDUCE VI
Page 201 and 202:
922 A STUDY OF PHOTOTOXICITY FOLLOW
Page 203 and 204:
from 0.1 to 2.9 g/L (saturated vapo
Page 205 and 206:
vasive method for assessing several
Page 207 and 208:
950 ARSENITE DOWN-REGULATES THE CAR
Page 209 and 210:
inflammatory signaling is altered b
Page 211 and 212:
treated wood. Seventy-five of 132 w
Page 213 and 214:
ergy homeostasis and raising levels
Page 215 and 216:
treated with mercury and then with
Page 217 and 218:
997 IN VIVO CORRELATES OF THE MANGA
Page 219 and 220:
of the panel. The panel was compris
Page 221 and 222:
sponse, location, and severity scor
Page 223 and 224:
tant source of n-3 fatty acids such
Page 225 and 226:
old for serious, irreversible or es
Page 227 and 228:
1045 SUBCHRONIC TOXICITY EVALUATION
Page 229 and 230:
sites collected 3 days after inject
Page 231 and 232:
1063 MOLECULAR MECHANISM OF OLANZAP
Page 233 and 234:
esponses, and can be available for
Page 235 and 236:
hence more physiologically relevant
Page 237 and 238:
thesized apoproteins, so we tested
Page 239 and 240:
vate CYP3A5 but could be released b
Page 241 and 242:
1108 STYRENE-INDUCED TOXIC EFFECTS
Page 243 and 244:
1118 THE PRESENCE OF DIETHYL FUMARA
Page 245 and 246:
zebrafish cells were first exposed
Page 247 and 248:
utene-1,4-dial, which has been show
Page 249 and 250:
groups, largely due to lower non-HD
Page 251 and 252:
Exposure to gluten in individuals w
Page 253 and 254:
contrast to VGSC activators such as
Page 255 and 256:
1175 70% HYDROFLUORIC ACID (HF) CUT
Page 257 and 258:
axis. An increase in hyaline drople
Page 259 and 260:
1194 esiRNA AND siRNA HIGH-THROUGHP
Page 261 and 262:
1203 ARYL HYDROCARBON RECEPTOR-DNA
Page 263 and 264:
permeability (calcein), mitochondri
Page 265 and 266:
olytic caspase activation, caspase-
Page 267 and 268:
teristics of a human T-type voltage
Page 269 and 270:
80% of the activity from the yellow
Page 271 and 272:
1251 DEVELOPMENTAL EXPOSURE TO DELT
Page 273 and 274:
1260 MANEB ENHANCES MPP + -INDUCED
Page 275 and 276:
demonstrated by knockdown of beclin
Page 277 and 278:
1278 PINK1 AND MITOCHONDRIAL DYNAMI
Page 279 and 280:
treatment for number of live worms.
Page 281 and 282:
1297 INVESTIGATION OF THE NEUROTOXI
Page 283 and 284:
1306 DEVELOPMENT OF AN IN VITRO ASS
Page 285 and 286:
1315 EVALUATION OF 3- AND 1-METHYLH
Page 287 and 288:
prior to kainic acid-induced seizur
Page 289 and 290:
1334 AFFECT OF GENETIC VARIATION ON
Page 291 and 292:
1346 THE OTHER WORLD OF THE TRANSCR
Page 293 and 294:
strate, leading to excess microvesi
Page 295 and 296:
1368 OVERVIEW OF THERAPEUTIC VACCIN
Page 297 and 298:
to a bovine adrenal cortical epithe
Page 299 and 300:
DOTC had no effects. These results
Page 301 and 302:
1398 PULMONARY TOXICITY OF CERIUM D
Page 303 and 304:
PPARα, LXR, ER, AR and AhR activit
Page 305 and 306:
1417 MECHANISM OF GENDER-DIVERGENT
Page 307 and 308:
els, they disrupt homeostatic contr
Page 309 and 310:
were to characterize exposure of th
Page 311 and 312:
1448 ADVERSE OUTCOME PATHWAYS AND E
Page 313 and 314:
the level in urine was 25% of the m
Page 315 and 316:
1;akt-2 double mutant and pdk-1 mut
Page 317 and 318:
jury effects when compared to contr
Page 319 and 320:
tude than equivalent oral doses. Af
Page 321 and 322:
cells; and increased iNOS and MCP-1
Page 323 and 324:
B6.Cg-Kit W-sh mice. These findings
Page 325 and 326:
1511 STATIN-TREATMENT EFFECTIVELY R
Page 327 and 328:
1520 EFFECT OF INHALATION EXPOSURE
Page 329 and 330:
numbers of IFN-γ producing cells w
Page 331 and 332:
These data indicate that TCDD treat
Page 333 and 334:
esponse to allogenic cells, where P
Page 335 and 336:
larly suppressed LPS-induced TNF-α
Page 337 and 338:
1565 INFLUENCE OF EXPOSURE ROUTE AN
Page 339 and 340:
veloping animals to adverse effects
Page 341 and 342:
the observed CL values were 0.07 L/
Page 343 and 344:
which is most relevant for potentia
Page 345 and 346:
tive impairment, suggesting that ox
Page 347 and 348:
1611 AN IN VITRO METABOLOMICS APPRO
Page 349 and 350:
Expression of the β6 integrin (Itg
Page 351 and 352:
ats (10 μg/kg TCDD). Here we repor
Page 353 and 354:
at liver slices and how the metabon
Page 355 and 356:
with gender differences in AUC and
Page 357 and 358:
oxetine (30 mg/kg reduced to 15 mg/
Page 359 and 360:
eleased from necrotic cells where i
Page 361 and 362:
plants, they are present in surface
Page 363 and 364:
ferentiation (quantitative in-cell
Page 365 and 366:
control for macrophage activation).
Page 367 and 368:
to 0.5μg/ml. Minimal inhibitory co
Page 369 and 370:
lines tested. Given that dex and AT
Page 371 and 372:
tion in the absence of an immune re
Page 373 and 374:
treated rats had lower calcium load
Page 375 and 376:
1740 PROFILING COMPOUNDS WITH CARDI
Page 377 and 378:
dothelial cells confirmed caveolin-
Page 379 and 380:
1758 GINKGO BILOBA EXTRACT INDUCES
Page 381 and 382:
arin-induced suppression of MDR1 ex
Page 383 and 384:
1780 ANTIANDROGENIC AND ANTIPROLIFE
Page 385 and 386:
included in the evaluation, most of
Page 387 and 388:
1799 GUIDANCE ON THE APPLICATION OF
Page 389 and 390:
However, substances with EC3 values
Page 391 and 392:
1816 CD-INDUCED EGFR TRANSACTIVATIO
Page 393 and 394:
1826 KERATIN 7 EXPRESSION IN INDEPE
Page 395 and 396:
centa were collected at the time of
Page 397 and 398:
1845 SYSTEMATIC SCREENING OF YEAST
Page 399 and 400:
underlying the development of co-mo
Page 401 and 402:
eing measured in experimental roden
Page 403 and 404:
ufactured in the US for more than 3
Page 405 and 406:
nine (N7-THB-Gua) and N7-hydroxyphe
Page 407 and 408:
1892 EFFECT OF LAMBDA-CYHALOTHRIN O
Page 409 and 410:
22 in Phase I. Antimicrobial pestic
Page 411 and 412:
kinetic and dynamic differences, an
Page 413 and 414:
iphenyl, saccharin and melamine was
Page 415 and 416:
1930 DEVELOPMENT OF A RELATIVE SOUR
Page 417 and 418:
1939 MODE OF ACTION FOR THE CANCER
Page 419 and 420:
human was about 1.5-fold lower (60
Page 421 and 422:
Disruption of BDEC integrity in alp
Page 423 and 424:
1968 A HUMAN HEPG2 LUCIFERASE ASSAY
Page 425 and 426:
in the offspring during tumor devel
Page 427 and 428:
een developed to investigate perfus
Page 429 and 430:
to 131.73 μg/mL for KLH-specific I
Page 431 and 432:
cell lines (ATCC) were cultured in
Page 433 and 434:
flammation and xenobiotic metabolis
Page 435 and 436:
vide many contributions: with its g
Page 437 and 438:
to-metal joint replacement. For exa
Page 439 and 440:
to be addressed or negotiated. Deci
Page 441 and 442:
especially with anti-TNF therapies.
Page 443 and 444:
genic line Tg(are:eGFP) was created
Page 445 and 446:
2074 COMPUTATIONAL ASSESSMENT OF TH
Page 447 and 448:
2084 INHIBITION OF 11β-HSD1 DECREA
Page 449 and 450:
(T) and express several enzymes inv
Page 451 and 452:
2101 GENISTEIN MODULATION OF BLOOD
Page 453 and 454:
males per group were dosed orally o
Page 455 and 456:
ate the feasibility of assessing re
Page 457 and 458:
changed. Hepatic protein carbonyl l
Page 459 and 460:
sought to examine alterations in he
Page 461 and 462:
2147 A SINGLE AMINO ACID CONTROLS T
Page 463 and 464:
Gstm7) was independent of both CAR
Page 465 and 466:
ility of tungsten trioxide (WO3), t
Page 467 and 468:
ured by real-time PCR array and rel
Page 469 and 470:
glucose, and creatinine levels, and
Page 471 and 472:
Several studies have reported suppr
Page 473 and 474:
exposure between TCDD-exposed labor
Page 475 and 476:
Furthermore, with increasing number
Page 477 and 478:
Society of Toxicology 2010 Author I
Page 479 and 480:
Page 481 and 482:
Page 483 and 484:
Page 485 and 486:
Page 487 and 488:
Page 489 and 490: Society of Toxicology 2010 Author I
Page 501 and 502: Society of Toxicology 2010 Abstract
Page 513 and 514: 49 th Annual Meeting and ToxExpo A
Page 539: 49 th Annual Meeting and ToxExpo A
Page 547 and 548: The Official Journal of the Society
show all

The Toxicologist - Society of Toxicology

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?